CELCUITY INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.92 USD | +0.95% |
|
-7.66% | +9.27% |
| 03-29 | Celcuity Inc. Enters into Second Amendment to its Existing Loan and Security Agreement | CI |
| 03-28 | Craig Hallum Adjusts Celcuity Price Target to $25 From $20, Maintains Buy Rating | MT |
| Sales 2024 * | 5.04M 404M | Sales 2025 * | 11.71M 938M | Capitalization | 485M 38.83B |
|---|---|---|---|---|---|
| Net income 2024 * | -86M -6.89B | Net income 2025 * | -127M -10.17B | EV / Sales 2024 * | 96.2 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 41.4 x |
| P/E ratio 2024 * |
-5.5
x | P/E ratio 2025 * |
-4.59
x | Employees | 55 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.63% |
More Fundamentals
* Assessed data
More news
Latest transcript on Celcuity Inc.
More recommendations
More press releases
| 1 day | +0.95% | ||
| 1 week | -7.66% | ||
| Current month | -26.30% | ||
| 1 month | -12.33% | ||
| 3 months | +8.08% | ||
| 6 months | +61.13% | ||
| Current year | +9.27% |
1 week
14.63
18.21
1 month
14.6322.04
Current year
13.4822.19
1 year
8.3922.19
3 years
4.8133.01
5 years
4.0333.01
10 years
4.0333.01
| Managers | Title | Age | Since |
|---|---|---|---|
Lance Laing
FOU | Founder | 62 | 31/12/11 |
Brian Sullivan
CEO | Chief Executive Officer | 62 | 31/12/11 |
Vicky Hahne
DFI | Director of Finance/CFO | 57 | 30/06/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Brian Sullivan
CEO | Chief Executive Officer | 62 | 31/12/11 |
Richard Nigon
BRD | Director/Board Member | 76 | 31/12/16 |
David Dalvey
BRD | Director/Board Member | 65 | 31/01/14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 15.92 | +0.95% | 668,444 |
| 25/04/24 | 15.77 | -6.91% | 228,657 |
| 24/04/24 | 16.94 | -1.74% | 90,283 |
| 23/04/24 | 17.24 | -1.71% | 90,649 |
| 22/04/24 | 17.54 | +1.74% | 405,133 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Calendar
07/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.92
USD
Average target price
29.5
USD
Spread / Average Target
+85.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.27% | 485M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CELC Stock
